The flag symbol  marks where the modification has been inserted.
In this CPG, sections 6.5.2. and Sumary Recommendations , an information note from the Spanish Agency of Medicine and Medical Devices (AEMPS) related to sibutramine has been inserted.
The modification inserted reads as follows:
| Summary of
recommendations and Section 6.5.2.
Marketing authorisation for sibutramine has been suspended as the risks outweig the benefits.
More information available at:
http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2010/NI_2010-01_sibutramina_reductil.htm [NOTE: website in spanish]
Last update: february 2013
Latest update: Enero 2009